地舒单抗联合运动对绝经后骨质疏松患者的临床研究

Clinical study of denosumab combined exercise on postmenopausal osteoporosis patients

目的研究地舒单抗联合运动对绝经后骨质疏松(PMOP)患者的影响。方法选取2020年6月至2021年10月重庆医科大学附属第一医院应用地舒单抗治疗的PMOP患者90例。随机分为两组,其中试验组为地舒单抗联合运动组(45例),对照组为单用地舒单抗组(45例),观察两组治疗前后腰椎骨密度(BMD)、总Ⅰ型胶原氨基端延长肽(TPINP)及β-特殊胶原系列(β-CROSSL)变化,以及试验组变化幅度是否优于对照组。结果两组治疗后6、12个月TPINP、β-CROSSL较治疗前均明显下降(P<0.05),且治疗时间越长,效果越明显;两组治疗后12个月腰椎BMD较治疗前均有显著增加(P<0.05),试验组腰椎BMD提升幅度优于对照组,但差异无统计学意义(P>0.05)。结论地舒单抗联合运动不仅能改善PMOP患者腰椎BMD,还能显著降低TPINP、β-CROSSL水平,值得临床推广。

Objective To investigate the effect of denosumab combined exercise on postmenopausal osteoporosis(PMO)patients.Methods A total of 90 PMO patients treated with denosumab in the First Affiliated Hospital of Chongqing Medical University from June 2020 to October 2021 were selected.They were randomly divided into two groups,among which the experimental group was treated with denosumab combined with exercise group and the control group was treated with denosumab alone.The changes of bone mineral density(BMD),total procollagen type1 intact N-terminal propeptide(TPINP)andβ-CrossLaps(β-CROSSL)before and after treatment in the two groups were observed,and whether the changes in the experimental group were better than those in the control group was observed.Results TPINP andβ-CROSSL decreased significantly in both groups in 6 months and 12 months after treatment compared with before treatment(P<0.05),and the longer the treatment time,the more obvious the effect;BMD of lumbar spine was significantly increased in both the groups 12 months after treatment compared with before treatment(P<0.05),and the increase of BMD of lumbar spine in the experimental group was better than that in the control group,but there was no significant difference(P>0.05).Conclusion Denosumab combined exercise can not only improve lumbar BMD in PMO patients,but also significantly reduce TPINP andβ-CROSSL levels,which is worthy of clinical promotion.